Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12220178 | 0.98 | GSK3B (0.52) | RAB9AGSK3BERCC5FEN1MAPT | |
| SCHEMBL11244190 | 0.87 | CXCR3 (0.45) | RAB9AGSK3BMAPTALDH1A1MITF | |
| SCHEMBL28841342 | 0.83 | MEN1 (0.45) | RAB9AGSK3BMAPTALDH1A1MITF | |
| Bromide SCHEMBL6073932 | 0.82 | KMT2A (0.54) | RAB9AGSK3BMAPTALDH1A1TP53 | |
| Bromide SCHEMBL6074363 | 0.81 | ALDH1A1 (0.49) | RAB9AGSK3BMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28841458 | 0.81 | GSK3B (0.42) | RAB9AGSK3BMAPTALDH1A1HTT | |
| SCHEMBL17966245 | 0.79 | ALDH1A1 (0.53) | RAB9AALDH1A1NPC1MGAMAMY1A | |
| Bromide SCHEMBL6074980 | 0.79 | SMN1; SMN2 (0.58) | RAB9AGSK3BERCC5FEN1MAPT | |
| Bromide SCHEMBL4114709 | 0.79 | RAB9A (0.46) | RAB9AGSK3BERCC5FEN1MAPT | |
| Bromide SCHEMBL6843500 | 0.78 | CXCR3 (0.49) | RAB9AMAPTALDH1A1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632914-B2 | Triazolium and imidazolium salts and uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-20 | — | — | US | disclosed |
| WO-2010025558-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF AS ANTIMALARIALS | UNIVERSITY HAEALTH NETWORK (CA) | 2010-03-11 | — | — | WO | disclosed |
| US-7022721-B1 | Method and composition for rejuvenating cells, tissues, organs, hair and nails | ULRICH PETER C | 2006-04-04 | — | — | US | disclosed |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | ULRICH PETER C | 2005-11-03 | — | — | US | disclosed |
| US-6777557-B2 | Method and composition for rejuvenating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2004-08-17 | — | — | US | disclosed |
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | RAB9A 1317/4885GSK3B 2693/4885ERCC5 778/4885 |
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | ARG2, ARG1, CIT | RAB9A 1643/4885GSK3B 3036/4885ERCC5 4060/4885 |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | RAB9A 1317/4885GSK3B 2693/4885ERCC5 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.